N/A N=46 REFRAME RPD Post-Market Clinical Study
Missing Teeth · Dental Wear
Primary: Change in Patient Oral Health-related Quality — 9.01; 14.41 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=248 Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin
Venous Leg Ulcer
Primary: Wound Area Change (%) — -49.7; -42.4 relative wound area change in percentage — p=0.093
Phase 1 N=6 Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects
Healthy Volunteers
Primary: Mass Balance Recovery of Total Radioactivity: CumAe (Urine) — 70.9 mg equiv
Phase 2 N=24 Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
Basal Cell Nevus Syndrome · Gorlin's Syndrome
Primary: Time to Recurrence to Baseline SEB Burden Following 7 Months of Continuous Vismodegib Treatment.
N/A N=33 Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
N/A N=25 Dispensing Study for the Phenacite Project
Ametropia
Primary: Subjective Ratings of Lens Comfort — 86.50; 90.13 units on a scale
Phase 1 N=52 Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate
Healthy
Primary: Relative Potency Max Heart Rate — 0.8619 unitless — p=>0.10
N/A N=765 DS-5565 Phase III Study for Post-herpetic Neuralgia
Post-Herpetic Neuralgia
Primary: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Oral Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia…
Phase 4 N=60 Antibiotic Elution in Total Knee Arthroplasty
Total Knee Replacement
Primary: Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty — 23.9; 30.6; 12.6; 16.2 mg/mL
N/A N=42 Sleep-Disordered Breathing in Chronic SCI
Spinal Cord Injury · Sleep Apnea, Obstructive
Primary: Cognitive Functioning as Measured by PASAT — 10.6; 15.2 score on a scale
Phase 3 N=834 DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Administration of DS-5565 in Participants With Diabetic Peripheral Neuropathic Pain…
Phase 3 N=16 A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
Erythropoietic Protoporphyria
Primary: Change in Quality of Life Measured Using the EPP-quality of Life Questionnaire (EPP-QoL). — 27.8; 59.7; 56.9 EPP-QoL score
Phase 4 N=12 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Systemic Sclerosis · Shortness of Breath · Pulmonary Hypertension
Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008